beta plaques

CRANAD-28 is a blood-brain barrier (BBB) penetrating two-photon imaging probe capable of visualizing amyloid plaques and labeling plaques and cerebral amyloid angiopathy.

β-Amyloid (1-14), mouse, rat, is a 1-14 fragment of the Amyloid-β peptide.

Amyloid precursor c-terminal peptide has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. APP is best known as the precursor molecule whose proteolysis generates beta-amyloid (Aβ), a 37 to 49 amino acid peptide whose am

β-Amyloid (11-22) is a peptide fragment of β-Amyloid. β-Amyloid peptide (Abeta), the primary component of amyloid plaques in the brains of Alzheimer’s patients, is believed to be the cause of Alzheimer’s Disease (AD), the most common neurodegenerative disease, affecting approximately 10% of the population over 60.

BIBD-124, with an IC50 value of 9.51 nM, effectively binds to amyloid beta (Aβ) plaques. The fluorinated variant, [18F]BIBD-124, serves as a radiotracer for imaging Aβ plaques [1].

Remternetug is a humanized IgG1-kappa monoclonal antibody that targets the N3pGlu peptide of the amyloid beta A4 precursor protein (APP) Aβ42. It specifically binds to the pyroglutamate-modified form of Aβ, which is implicated in the aggregation of amyloid plaques [1].